for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
  PharmAsia News
   Full-text available via subscription Subscription journal
   ISSN (Print) 1875-7774
   Published by Informa plc Homepage  [14 journals]
  • China Slump Holds Back GSK’s International Pharma Sales
    • Abstract: GlaxoSmithKline has joined the ranks of other multinational pharma firms including Lilly and Novartis that have seen a slump in their China business in the second quarter. A global restructuring program as well as some capacity constraints also affected the quarterly international sales of the British firm's global pharma business.
      PubDate: Fri, 31 Jul 2015 03:40:01 -040
  • Korea Mulls Moves To Aid Smaller Pharma Firms
    • Abstract: South Korea's Ministry of Food and Drug Safety has suggested steps to help small- and medium-sized pharma firms in the country overcome difficulties stemming from increased investment costs, lower drug prices and the MERS outbreak. The measures include forming a consultative group to discuss obstacles and mutual cooperation at the development and other stages.
      PubDate: Fri, 31 Jul 2015 00:50:01 -040
  • Lower China Growth For Takeda, But Impact Limited
    • Abstract: In line with some of its larger multinational peers, Takeda saw weaker growth in China over the past three months, although its relatively small exposure to emerging markets and increases for new products in major markets mean investors do not appear concerned.
      PubDate: Thu, 30 Jul 2015 23:00:00 -040
  • Yabao Links With Lawson For Innovative Sepsis Drug
    • Abstract: With the aim of providing new cures for a global unmet medical need in sepsis, China’s Yabao Pharmaceutical and its strategic partner Lawson have completed discovery validation work for annexin A5-based products under a newly announced license agreement. An IND filing is expected in 2016.
      PubDate: Thu, 30 Jul 2015 20:00:00 -040
  • Turkey Regulatory Update: Faster Approvals and Better Access
    • Abstract: The registration process in Turkey for selected new drugs is to be accelerated, while patients are starting to receive their cancer treatments from hospitals under a new system. Meanwhile more than 100 drugs remain inaccessible to Turkish patients and an influential academician has warned against hepatitis A vaccines produced in China.
      PubDate: Thu, 30 Jul 2015 02:40:01 -040
  • Lilly Hit By China 2Q Contraction
    • Abstract: Not all pharma multinationals have provided details of their emerging markets performance in the second quarter, but for those that have, it is clear that growth in China has slowed dramatically over the past few months. Lilly was among those to concede to current challenges in this major emerging market, although it remains bullish on long term prospects.
      PubDate: Thu, 30 Jul 2015 01:50:02 -040
  • Novartis China Growth Slows Sharply In 2Q
    • Abstract: China’s economic slowdown has hit Novartis hard, with the Swiss multinational’s second quarter growth in the country being slashed by around half. Despite the company emphasizing the challenges are short-term, the underlying reasons such as growing generic competition from domestic companies could be far-reaching.
      PubDate: Thu, 30 Jul 2015 01:25:01 -040
  • Can India’s Syngene Best WuXi'
    • Abstract: Syngene's initial public offering (IPO) opened for subscription in India on 27 July, amid generally encouraging reviews and favorable comparisons with China's WuXi PharmaTech. Syngene is part of the Indian firm Biocon, and like WuXi provides a range of contract research services to the pharma industry.
      PubDate: Thu, 30 Jul 2015 00:55:01 -040
  • Shenogen’s Icaritin: A New First-Line Therapy For HCC'
    • Abstract: Preliminary data from a Phase II study has unveiled promising results for Shenogen’s icaritin, a plant-derived product being studied as a possible therapy for hepatocellular carcinoma. The drug’s safety profile makes it particularly appealing, says the Chinese startup’s chief business officer.
      PubDate: Wed, 29 Jul 2015 21:20:02 -040
  • Japan’s AMED Taps Genomics In Rare Disease Project
    • Abstract: Making good on plans outlined earlier this year, and mirroring similar initiatives elsewhere, Japan's new Agency for Medical R&D has kicked off a new project to use genome analysis to help identify and treat rare diseases, as part of its remit to encourage collaborative research and promote public health.
      PubDate: Wed, 29 Jul 2015 01:55:01 -040
  • ANALYSIS: Hanmi Deal Strengthens BI’s Hand But Competitors Ahead
    • Abstract: Hanmi’s third-generation EGFR inhibitor HM61713, acquired for $50 million up front, strongly complements Boehringer Ingelheim’s existing oncology drug Gilotrif/Giotrif, but the new asset is facing competitors from AstraZeneca and Clovis that are more advanced in development.
      PubDate: Wed, 29 Jul 2015 01:45:00 -040
  • Medytox In China JV Deal, Aims To Set Up More Asian Units
    • Abstract: After the establishment of its first overseas subsidiary in Taiwan early this year, Medytox has set up a joint venture with China's Bloomage BioTechnology to sell its botulinum toxin products and hyaluronic acid fillers in China. The South Korean biopharma company is aiming to establish more subsidiaries in other major Asian countries as part of plans to directly sell its products in the region.
      PubDate: Wed, 29 Jul 2015 01:10:00 -040
  • EU Confirms Suspension Of 700 Generics But Indian Impact Unclear
    • Abstract: An EU order to pull some 700 generic drug products off retail shelves over testing quality issues could cut India’s pharmaceutical annual exports by at least $1 billion, according to a government body, although there is some disagreement over the likely actual impact. The suspension has also fuelled fresh doubts about the standards followed by India's troubled clinical trials industry.
      PubDate: Wed, 29 Jul 2015 00:00:26 -040
  • 3SBio Acquires Wansheng To Bolster Small Molecule Portfolio
    • Abstract: China’s 3SBio has been actively scouting M&A targets in both overseas and domestic markets, aiming to enrich its product pipeline and diversify its offering. It has now landed its first acquisition, of a chemical drug maker in China, just one month after its Hong Kong IPO, in a deal that will provide 3SBio with an integrated small molecule R&D and manufacturing platform and increase its manufacturing cost competitiveness.
      PubDate: Tue, 28 Jul 2015 22:20:00 -040
  • Hanmi Inks Record Korean Deal, With Boehringer For Cancer Therapy
    • Abstract: Hanmi Pharmaceutical continues to lead South Korean pharma innovators by reaching a series of major licensing out deals. Following the major agreement with Lilly for its oral Bruton's tyrosine kinase inhibitor earlier this year, Hanmi has now inked an even bigger license agreement with Boehringer Ingelheim, for a novel non-small cell lung cancer therapy HM61713 that will beef up the German firm's oncology portfolio.
      PubDate: Tue, 28 Jul 2015 07:50:02 -040
  • Turkey Firms Up More Positive Policies As It Seeks Biotech Boost
    • Abstract: Having prepared a Biotechnology Strategy Document and Action Plan last year, Turkey now seems to have a roadmap in this sector. The blueprint includes many policies that the research-based pharmaceutical industry has been advocating for at least 10 years, such as promoting biotech investments through legal reforms to strengthen intellectual property rights and boosting transparent and predictable public policies for market access and reimbursement.
      PubDate: Tue, 28 Jul 2015 02:10:00 -040
  • Shanghai Eyed For Second China Drug Review Center
    • Abstract: The city that many multinational drug firms call home in China is reportedly contemplating building a regional center for drug evaluation under the China FDA, sharing the burden of the current similar center in Beijing. PharmAsia News talks to a former official and legal expert on the reasons behind, and prospects for, the proposal.
      PubDate: Mon, 27 Jul 2015 21:00:01 -040
  • Australia Gearing Up For More Price Cuts This Year And Next
    • Abstract: Innovator companies are facing the prospect of more significant falls in the prices of medicines paid for by the Pharmaceutical Benefits Scheme (PBS) after the Australian government launched a consultation on changes to the price disclosure process that are due to take effect in October next year.
      PubDate: Mon, 27 Jul 2015 20:15:03 -040
  • AstraZeneca Tests Biosimilar Waters Through Bevacizumab JV
    • Abstract: AstraZeneca and Japan's Fujifilm Kyowa Kirin Biologics have signed an agreement to set up a UK-based joint venture to develop globally a biosimilar version of bevacizumab, marking the first tentative step into the biosimilars sector by the research-based pharma giant.
      PubDate: Mon, 27 Jul 2015 03:30:01 -040
  • Biocon Betting Big On Biosimilars As Profit Jumps
    • Abstract: Biocon, India’s biggest biotechnology company, has just reported a 23% year-on-year jump in quarterly net profit, and says it has sharply boosted its research and development spend as it bets heavily on biosimilars.
      PubDate: Mon, 27 Jul 2015 02:00:01 -040
  • INTERVIEW: Dong-A Seeks Partners For Global Expansion Push
    • Abstract: With a goal of becoming a truly global biopharma firm, Dong-A is now stepping up its R&D efforts like many other leading South Korean pharma companies. In an interview with PharmAsia News, a senior company executive talks about strategies for overseas business development including plans for biosimilars and original new drug candidates.
      PubDate: Mon, 27 Jul 2015 00:03:40 -040
  • KHK Preps Japan Filing For Brodalumab Despite Setbacks Elsewhere
    • Abstract: Despite adverse event concerns that have led to the dissolution of one international alliance for the drug, Kyowa Hakko Kirin is pushing ahead with plans for a Japanese approval filing for brodalumab for psoriasis.
      PubDate: Sun, 26 Jul 2015 20:05:00 -040
  • CFDA Surprises Industry With Clinical Data Self-Audit Notice
    • Abstract: Drug makers have 34 days to self-audit the clinical data submitted in their clinical trial or new drug filings, and to submit an authentication report bearing legal representatives’ signatures. Those failing to do so will face unannounced inspections and may have to voluntarily withdraw their regulatory filings, the China FDA has warned.
      PubDate: Fri, 24 Jul 2015 02:10:00 -040
  • Bukwang Acquires Acer Stake In Pattern Of Venture Investments
    • Abstract: Bukwang Pharm has purchased a minority stake in U.S. bioventure Acer Therapeutics, which is seeking to list its shares on Nasdaq early next year. The investment is the sixth the South Korean firm has made together with TVM Life Science Capital to gain investment returns and beef up R&D.
      PubDate: Thu, 23 Jul 2015 23:05:00 -040
  • INTERVIEW: Hilleman Seeks Hib Partners As It Hones Focus
    • Abstract: Indian vaccine R&D firm Hilleman Laboratories says it's talking to potential partners about the clinical testing of a new "breakthrough" vaccine formulation that could create a far cheaper, more effective way to combat Haemophilus influenzae type b (Hib) and be in production in the next three to four years.
      PubDate: Thu, 23 Jul 2015 19:40:12 -040
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015